The cumulative incidence of breast cancer in women with TP53 PVs is estimated to be 85% by the age of 60 years [11] and the risk of second cancers, associated with Li-Fraumeni syndrome (LFS), is high. The gene discussed is TP53; the disease is Li-Fraumeni syndrome.